NCT01363388View on ClinicalTrials.gov

A Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With ANCA-Associated Vasculitis

PHASE2CompletedINTERVENTIONAL

Enrollment

67

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

October 31, 2015

Study Completion Date

January 31, 2016

Conditions

Vasculitis

Interventions

DRUG

Placebo

BID for 84 days

DRUG

CCX168

BID for 84 days

Trial Locations (44)

Unknown

Feldkirch

Innsbruck

Linz

Brussels

Edegem

Ghent

Leuven

Liège

Roeselare

Prague

Bordeaux

Boulogne-sur-Mer

Brest

Colmar

Grenoble

Nantes

Paris

Saint-Jacques

Valenciennes

Berlin

Cologne

Dresden

Freiburg im Breisgau

Fulda

Heidelberg

Budapest

Groningen

Leiden

Rotterdam

Utrecht

Bialystok

Katowice

Szczecin

Wroclaw

Linköping

Lund

Malmo

Stockholm

Birmingham

Cambridge

London

Manchester

Oxford

Reading

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Amgen

INDUSTRY